Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK5733584 · 1 trial · 1 indication
PFS is defined as the time from the date of randomization to the date of first documented Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by Blinded independent central review (BICR) assessment or death from any cause, whichever occurs first
| Arm | Type | Description |
|---|---|---|
| Mocertatug rezetecan plus physician's choice of immunotherapy (dostarlimab or pembrolizumab) | EXPERIMENTAL | Participants will receive Mocertatug rezetecan along with physician's choice of immunotherapy (Dostarlimab or Pembrolizumab) |
| Physician's choice of immunotherapy (dostarlimab or pembrolizumab) | ACTIVE_COMPARATOR | Participants will receive physician's choice of immunotherapy (Dostarlimab or Pembrolizumab alone) |
| Name | Type | Description |
|---|---|---|
| Mocertatug rezetecan | DRUG | Mocertatug rezetecan will be administered |
| Dostarlimab | DRUG | Dostarlimab will be administered |
| Pembrolizumab | DRUG | Pembrolizumab will be administered |
Inclusion Criteria: * Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed consent form (ICF). * Has received 6 cycles of first-line therapy (i.e. induction therapy), consisting of platinum-based doublet ...
GSK5733584 is an investigational small molecule being studied for the treatment of endometrial neoplasms, specifically in patients with mismatch repair proficient (MMRp) endometrial cancer. It is currently in Phase 3 clinical development as a maintenance treatment for this condition.
GSK5733584 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting a Phase 3 clinical trial to evaluate the drug as a maintenance treatment for endometrial cancer.
GSK5733584 is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is designed to evaluate its efficacy and safety as a maintenance treatment for patients with MMRp endometrial cancer.
GSK5733584 is being studied in a Phase 3 clinical trial with the identifier NCT07684599. This trial, titled 'A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)', is not yet recruiting and aims to enroll 610 female participants aged 18 years and older.
Yes, GSK5733584 is also known as Mocertatug Rezetecan. The Phase 3 clinical trial NCT07684599 uses the name Mocertatug Rezetecan to refer to the drug being investigated as a maintenance treatment for participants with MMRp endometrial cancer.